Robotic partial nephrectomy for renal tumor: The pentafecta outcomes of a single surgeon experience

Bo-Ren Wang(Taichung Armed Forces General Hospital), Min‐Che Tung(National Chung Hsing University), Chin-Heng Lu(Tungs' Taichung MetroHarbor Hospital), Li‐Hua Huang(Zhujiang Hospital), Yen‐Chuan Ou(Tungs' Taichung MetroHarbor Hospital), Cheng‐Kuang Yang(Taichung Veterans General Hospital), Wei‐Chun Weng(Mackay Junior College of Medicine, Nursing and Management), Yi‐Sheng Lin(Peking University), Chao‐Yu Hsu(National Chung Hsing University), Yu‐Kang Chang(Tungs' Taichung MetroHarbor Hospital)
Asian Journal of Surgery
August 30, 2023
10.1016/j.asjsur.2023.05.140
Cited by 5

Related Papers

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
|The Lancet|2017|177
Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience
|European Urology|2006|176
Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients
|European Urology|2010|154
Pathological results and rates of treatment failure in high‐risk prostate cancer patients after radical prostatectomy
|British Journal of Urology|2010|141